Alzheimer's therapeutics: Translation of preclinical science to clinical drug development

Neuropsychopharmacology

Volumn 37, Issue 1, 2012, Pages 261-277

  Savonenko, Alena V ^a   Melnikova, Tatiana ^a   Hiatt, Andrew ^b   Li, Tong ^a   Worley, Paul F ^a   Troncoso, Juan C ^a   Wong, Phil C ^a   Price, Don L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mapp Biopharmaceutical   (United States)

Author keywords

acetylcholinesterase inhibitors; amyloid cascade; animal models; anti Ab immunization; g secretase inhibition; neurodegeneration

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; CTS 21166; DIMEBON; GAMMA INTERFERON; GAMMA SECRETASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SEMAGACESTAT; SOMATOSTATIN; TAK 070; TAU PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIBODY TITER; ASEPTIC MENINGOENCEPHALITIS; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CELL MIGRATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84856108244     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.211     Document Type: Review

References (179)

1. Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ et al (2008). Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gammasecretase inhibition. J Pharmacol Exp Ther 327: 411-424.
2. Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P et al (2001). Behavioral assessment of Alzheimer's transgenic mice following longterm Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol 20: 737-744. (Pubitemid 34072841)
3. Bartus RT (1979). Physostigmine and recent memory: effects in young and aged nonhuman primates. Science 206: 1087-1089. (Pubitemid 10208884)
4. Bartus RT, Dean 3rd RL, Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-414.
5. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC et al (2009). A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66: 48-54.
6. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A (2001). Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 905: 220-223. (Pubitemid 32553856)
7. Bertram L, Tanzi RE (2009). Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 18: R137-R145.
8. Birks J (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev(1): CD005593.
9. Black W, Almeida OP (2004). A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Psychogeriatr 16: 295-315. (Pubitemid 39441494)
10. Boche D, Denham N, Holmes C, Nicoll JA (2010). Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120: 369-384.
11. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA et al (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-945. (Pubitemid 27471397)
12. Bowen DM, Smith CB, White P, Davison AN (1976). Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99: 459-496.
13. Braak H, Braak E (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
14. Brousseau G, Rourke BP, Burke B (2007). Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. Exp Clin Psychopharmacol 15: 546-554. (Pubitemid 351163129)
15. Brunden KR, Trojanowski JQ, Lee VM (2008). Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis 14: 393-399.
16. Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ et al (2008). The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem 283: 22992-23003.
17. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K et al (2005). Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 25: 9096-9101. (Pubitemid 41500817)
18. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A et al (2006). M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49: 671-682. (Pubitemid 43290127)
19. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL et al (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4: 233-234. (Pubitemid 32194867)
20. Cappell J, Herrmann N, Cornish S, Lanctot KL (2010). The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 24: 909-927.
21. Caughey B, Lansbury PT (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-298. (Pubitemid 37064935)
22. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM et al (2011). Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 25: 775-784.
23. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V et al (2004). In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89: 1409-1416. (Pubitemid 38802662)
24. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ et al (2000). A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975-979. (Pubitemid 32101643)
25. Chen G, Chen KS, Kobayashi D, Barbour R, Motter R, Games D et al (2007). Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci 27: 2654-2662. (Pubitemid 46393609)
26. Chow VW, Savonenko AV, Melnikova T, Kim H, Price DL, Li T et al (2010). Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med 2: 13ra11.
27. Citron M (2002). Emerging Alzheimer's disease therapies: inhibition of betasecretase. Neurobiol Aging 23: 1017-1022. (Pubitemid 35447782)
28. Citron M (2010). Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398.
29. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ (1996). Evidence that the 42-and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 93: 13170-13175. (Pubitemid 26382788)
30. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P et al (1992). Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672-674. (Pubitemid 23007680)
31. Coyle JT, Price DL, DeLong MR (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190. (Pubitemid 13160659)
32. Cummings JL (2004). Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis 1: 60-69.
33. Das P, Chapoval S, Howard V, David CS, Golde TE (2003). Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. Neurobiol Aging 24: 969-976. (Pubitemid 36962983)
34. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE (2001). Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22: 721-727. (Pubitemid 33055611)
35. Davies P, Maloney AJ (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403. (Pubitemid 8004505)
36. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M et al (1999). Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281: 1401-1406. (Pubitemid 29190218)
37. Davis KL, Mohs RC, Tinklenberg JR (1979). Enhancement of memory by physostigmine. N Engl J Med 301: 946. (Pubitemid 10198042)
38. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS (1978). Physostigmine: improvement of long-term memory processes in normal humans. Science 201: 272-274. (Pubitemid 8396755)
39. De Strooper B (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38: 9-12. (Pubitemid 36423348)
40. De Strooper B, Vassar R, Golde T (2010). The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6: 99-107.
41. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA et al (2002). Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51: 145-155. (Pubitemid 34111436)
42. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002). Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295: 2264-2267. (Pubitemid 34258840)
43. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW et al (2004). ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41: 193-202. (Pubitemid 38125181)
44. Digby GJ, Shirey JK, Conn PJ (2010). Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst 6: 1345-1354.
45. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C et al (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457. (Pubitemid 34454251)
46. Eriksen JL, Janus CG (2007). Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet 37: 79-100. (Pubitemid 46150856)
47. Falls DL (2003). Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14-30. (Pubitemid 36335807)
48. Fisher A (2007). M1 muscarinic agonists target major hallmarks of Alzheimer's disease-an update. Curr Alzheimer Res 4: 577-580. (Pubitemid 350248396)
49. Francis PT, Nordberg A, Arnold SE (2005). A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 26: 104-111. (Pubitemid 40170173)
50. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M et al (2010). A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 30: 11157-11166.
51. Gauthier S, Loft H, Cummings J (2008). Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 23: 537-545. (Pubitemid 351722115)
52. German DC, Manaye KF, White 3rd CL, Woodward DJ, McIntire DD, Smith WK et al (1992). Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32: 667-676.
53. Ghosh AK, Gemma S, Tang J (2008). beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 5: 399-408. (Pubitemid 351952491)
54. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP et al (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60: 1495-1500. (Pubitemid 36559525)
55. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC et al (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562. (Pubitemid 40617691)
56. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ et al (1999). Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 411: 693-704. (Pubitemid 29368199)
57. Golde TE, Schneider LS, Koo EH (2011). Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69: 203-213.
58. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE et al (2001). Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22: 377-385. (Pubitemid 32510908)
59. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495. (Pubitemid 32807681)
60. Haass C (2002). New hope for Alzheimer disease vaccine. Nat Med 8: 1195-1196. (Pubitemid 35373542)
61. Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS et al (2001). Gamma-secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 98: 7487-7491. (Pubitemid 32567975)
62. Hardy J (1996). New insights into the genetics of Alzheimer's disease. Ann Med 28: 255-258. (Pubitemid 26191063)
63. Hardy JA, Higgins GA (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
64. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J et al (2010). Gammasecretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467: 95-98.
65. Henley DB, May PC, Dean RA, Siemers ER (2009). Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 10: 1657-1664.
66. Herrup K (2010). Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 30: 16755-16762.
67. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC et al (2002). Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8: 1270-1275. (Pubitemid 35373559)
68. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B et al (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554. (Pubitemid 36645030)
69. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A et al (2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223. (Pubitemid 351978111)
70. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD et al (2006). Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9: 1520-1525. (Pubitemid 44862660)
71. Jankowsky JL, Savonenko A, Schilling G, Wang J, Xu G, Borchelt DR (2002). Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr Neurol Neurosci Rep 2: 457-464.
72. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982. (Pubitemid 32101644)
73. Jaworski T, Dewachter I, Seymour CM, Borghgraef P, Devijver H, Kugler S et al (2010). Alzheimer's disease: old problem, new views from transgenic and viral models. Biochim Biophys Acta 1802: 808-818.
74. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T et al (2003). APP processing and synaptic function. Neuron 37: 925-937. (Pubitemid 36398299)
75. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M et al (2007). Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18.
76. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW et al (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489. (Pubitemid 36444329)
77. Kenton L, Boon F, Cain DP (2008). Combined but not individual administration of beta-adrenergic and serotonergic antagonists impairs water maze acquisition in the rat. Neuropsychopharmacology 33: 1298-1311. (Pubitemid 351521723)
78. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T et al (2011). Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76: 69-79.
79. Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y (2001). Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA 98: 13554-13559. (Pubitemid 33115936)
80. Klegeris A, McGeer EG, McGeer PL (2007). Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20: 351-357. (Pubitemid 46743120)
81. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT et al (2002). Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22: 6331-6335. (Pubitemid 35386387)
82. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M et al (2010). Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 29: 3408-3420.
83. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T et al (2005). BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693-11709. (Pubitemid 43098462)
84. Lanctot KL, Herrmann N, LouLou MM (2003a). Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci 28: 13-26. (Pubitemid 36315348)
85. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM et al (2003b). Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a metaanalysis. CMAJ 169: 557-564. (Pubitemid 37174596)
86. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B et al (2003). The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305: 864-871. (Pubitemid 36617962)
87. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA et al (2006). Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319: 924-933.
88. Lee EB, Leng LZ, Lee VM, Trojanowski JQ (2005). Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett 579: 2564-2568. (Pubitemid 40615659)
89. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T et al (2006). Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-4299. (Pubitemid 43847859)
90. Lee VM, Goedert M, Trojanowski JQ (2001). Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159. (Pubitemid 32695256)
91. Lemere CA, Masliah E (2010). Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119.
92. Lesne S, Kotilinek L, Ashe KH (2008). Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151: 745-749.
93. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G et al (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491. (Pubitemid 32801551)
94. Li Q, Sudhof TC (2004). Cleavage of amyloid-beta precursor protein and amyloidbeta precursor-like protein by BACE 1. J Biol Chem 279: 10542-10550. (Pubitemid 38372665)
95. Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S et al (2007). Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 27: 10849-10859. (Pubitemid 47535873)
96. Lipton SA (2005). The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2: 155-165. (Pubitemid 40862876)
97. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR et al (2008). Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28: 13805-13814.
98. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA et al (2009). Longterm effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80: 600-607.
99. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4: 231-232. (Pubitemid 32194866)
100. Marcyniuk B, Mann DM, Yates PO (1986). The topography of cell loss from locus coeruleus in Alzheimer's disease. J Neurol Sci 76: 335-345. (Pubitemid 17176089)
101. May PC, Yang Z, Li W, Hyslop PA, Siemers ER, Boggs L (2004). Multicompartmental pharmaco-dynamic assessment of teh functional gammasecretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging S 1: S65.
102. McArthur B, Borsini F (2008). Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders, vol 1. Elsevier. p 528.
103. McEver RP, Cummings RD (1997). Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 100: S97-103. (Pubitemid 28009555)
104. McGowan E, Eriksen J, Hutton M (2006). A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22: 281-289.
105. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M et al (2002). Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269. (Pubitemid 35373558)
106. Mecocci P, Bladstrom A, Stender K (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 24: 532-538.
107. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C et al (2004). Axonal neuregulin-1 regulates myelin sheath thickness. Science 304: 700-703. (Pubitemid 38560869)
108. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R et al (2006). Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103: 5048-5053.
109. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J et al (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985. (Pubitemid 32101645)
110. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P et al (2000). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577. (Pubitemid 30161512)
111. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M et al (2003). Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33: 416-421. (Pubitemid 36278861)
112. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003). Neuropathology of human Alzheimer disease after immunization with amyloidbeta peptide: a case report. Nat Med 9: 448-452. (Pubitemid 36460079)
113. O'Brien JT, Burns A (2010). Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol.
114. O'Nuallain B, Wetzel R (2002). Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99: 1485-1490. (Pubitemid 34136519)
115. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421. (Pubitemid 36937044)
116. Oddo S, LaFerla FM (2006). The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris 99: 172-179.
117. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006). Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281: 39413-39423. (Pubitemid 46041901)
118. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M et al (2004). BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41: 27-33. (Pubitemid 38071826)
119. Okun I, Tkachenko SE, Khvat A, Mitkin O, Kazey V, Ivachtchenko AV (2010). From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon. Curr Alzheimer Res 7: 97-112.
120. Olton DS, Feustle WA (1981). Hippocampal function required for nonspatial working memory. Exp Brain Res 41: 380-389. (Pubitemid 11142846)
121. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54. (Pubitemid 36818745)
122. Parvizi J, Van Hoesen GW, Damasio A (2001). The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 49: 53-66. (Pubitemid 32163006)
123. Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K et al (2004). BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25: 642-649. (Pubitemid 38481473)
124. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2: 1457-1459. (Pubitemid 9061468)
125. Perry VH, Nicoll JA, Holmes C (2010). Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201.
126. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M et al (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379. (Pubitemid 35346131)
127. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010). Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 30: 14946-14954.
128. Pinto T, Lanctot KL, Herrmann N (2011). Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev 10: 404-412.
129. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008). Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5: 83-89. (Pubitemid 351536358)
130. Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E et al (2010). A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2: 7.
131. Price D, Martin L, Savonenko A, Li T, Laird F, Wong P (2007). Selected Genetically Engineered Models Relevant to Human Neurodegenerative Disease. In: Rosenberg RN, Di Mauro S, Paulson H, Ptacek L and Nestler E (eds). The Molecular and Genetic Basis of Neurological and Psychiatric Disease. Lippincott Williams & Wilkins. pp. 35-62.
132. Price DL, Tanzi RE, Borchelt DR, Sisodia SS (1998). Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 32: 461-493. (Pubitemid 29045321)
133. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK et al (2005). Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25: 629-636.
134. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341. (Pubitemid 36384100)
135. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L (2008). Rational targeting of Notch signaling in cancer. Oncogene 27: 5124-5131.
136. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS et al (2001). BACE knockout mice are healthy despite lacking the primary betasecretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317-1324. (Pubitemid 32600485)
137. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754. (Pubitemid 46717684)
138. Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebocontrolled study. Donepezil Study Group. Arch Intern Med 158: 1021-1031. (Pubitemid 28213580)
139. Rossor MN, Iversen LL, Mountjoy CQ, Roth M, Hawthorn J, Ang VY et al (1980). Arginine vasopressin and choline acetyltransferase in brains of patients with Alzheimer type senile dementia. Lancet 2: 1367-1368. (Pubitemid 11253192)
140. Sabbagh M, Cummings J (2011). Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23mg in patients with moderate to severe symptomatology. BMC Neurol 11: 21.
141. Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM et al (2005). Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11: 434-439. (Pubitemid 40562335)
142. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M et al (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
143. Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K et al (2008). In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 324: 957-969. (Pubitemid 351397853)
144. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M et al (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481. (Pubitemid 40994688)
145. Savonenko A, Laird F, Troncoso J, Wong P, Price D (2005a). Role of Alzheimer's disease models in designing and testing experimental therapeutics. Drug Discov Today 2: 305-312. (Pubitemid 43071698)
146. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP et al (2005b). Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-617. (Pubitemid 40332718)
147. Savonenko AV, Borchelt DL (2008). Transgenic mouse models of Alzheimer's disease and episodic memory. In: Dere E, Easton A, Nadel L and Huston JP(eds). Handbook of Episodic Memory. Elsevier. pp. 553-573.
148. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC (2008). Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 105: 5585-5590. (Pubitemid 351753906)
149. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177. (Pubitemid 29327547)
150. Schneider A, Mandelkow E (2008). Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5: 443-457. (Pubitemid 351952490)
151. Schneider LS, Insel PS, Weiner MW (2011). Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 68: 58-66.
152. Selkoe DJ, Schenk D (2003). Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545-584. (Pubitemid 37372653)
153. Senior K (2002). Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 1: 3.
154. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760.
155. Shimohama S, Kihara T (2001). Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psychiatry 49: 233-239. (Pubitemid 32178432)
156. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M et al (2005). Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28: 126-132. (Pubitemid 40923411)
157. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM et al (2010). Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33: 67-73.
158. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D et al (2004). An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24: 6277-6282. (Pubitemid 38944217)
159. Spooner ET, Desai RV, Mori C, Leverone JF, Lemere CA (2002). The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Vaccine 21: 290-297. (Pubitemid 35346823)
160. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71: 877-892. (Pubitemid 135750519)
161. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317-324. (Pubitemid 38101604)
162. Tomic JL, Pensalfini A, Head E, Glabe CG (2009). Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358.
163. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H et al (2005). Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963. (Pubitemid 40896322)
164. Vassar R (2002). Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Deliv Rev 54: 1589-1602. (Pubitemid 35346833)
165. Vassar R, Kovacs DM, Yan R, Wong PC (2009). The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29: 12787-12794.
166. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM et al (2005). The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 280: 17777-17785. (Pubitemid 41389016)
167. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL (1994). Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14: 167-186. (Pubitemid 24022106)
168. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539. (Pubitemid 34288854)
169. Wang A, Das P, Switzer 3rd RC, Golde TE, Jankowsky JL (2011). Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-\{beta\} immunothera. J Neurosci 31: 4124-4136.
170. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH et al (2002). The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22: 1858-1867. (Pubitemid 35386304)
171. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982). Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237-1239. (Pubitemid 12106486)
172. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J et al (2006). Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26: 5340-5346. (Pubitemid 44318386)
173. Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA (2009). Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 29: 7957-7965.
174. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN et al (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24.
175. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A et al (2006). Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314: 664-666. (Pubitemid 44646394)
176. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H et al (2005). beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 280: 23009-23017. (Pubitemid 40853211)
177. Wong PC, Price DL (2005). Neurobiology of Alzheimer's Disease. In: Brady ST, Siegel GD, Albers RW and Price DL (eds). Basic Neurochemistry. Elsevier. pp. 781-790.
178. Woodcock J, Griffin JP, Behrman RE (2011). Development of novel combination therapies. N Engl J Med 364: 985-987.
179. Zhang L, Song L, Terracina G, Liu Y, Pramanik B, Parker E (2001). Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. Biochemistry 40: 5049-5055 (Pubitemid 32332551)